PFE
PFE
$28.85
$-0.60 (-2.04%)
About
No description available for this stock.
Price History (Last 30 Days)
Latest News & Updates
DelveInsight released a comprehensive competitive landscape report on BCMA-targe...
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
Moderna shares gained 3% following better-than-expected Q3 2026 earnings and rai...
Moderna shares gained 3% following better-than-expected Q3 2026 earnings and raised full-year revenue guidance to 15-25% growth, driven by stronger international COVID-19 vaccine sales. The company's oncology pipeline, particularly its personalized cancer therapy intismeran developed with Merck, showed promising phase III results with a 42% reduction in recurrence or death risk. Despite premium valuation and ongoing cash burn concerns, Moderna maintains a Zacks Rank #2 (Buy) rating, supported by expanding respiratory vaccine portfolio and oncology opportunities.
Pfizer announced a strategic co-funding agreement with Blackstone Life Sciences...
Pfizer announced a strategic co-funding agreement with Blackstone Life Sciences to secure up to $1.5 billion to advance berobenatide, its investigational monthly GLP-1 receptor agonist for obesity treatment. The funding will support 10 planned Phase III studies through 2028, with Pfizer retaining full control of the program. Blackstone will receive milestone-based payments tied to regulatory approval and commercial sales milestones.
Eli Lilly has established itself as a dominant player in the obesity treatment m...
Eli Lilly has established itself as a dominant player in the obesity treatment market, with Mounjaro and Zepbound generating 65% of revenues. The company's April 2026 launch of Foundayo (oral GLP-1) recorded $281 million in sales, offering a more convenient alternative to injectable treatments. Lilly is developing next-generation therapies including retatrutide (triple-acting), eloralintide, and EloraTZP to maintain market leadership. However, competition is intensifying from Novo Nordisk and emerging biotech companies.
DelveInsight released a comprehensive competitive landscape report on GLP-1 rece...
DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.
The global injectables market is projected to grow from USD 765 billion in 2025...
The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.
Arvinas, a clinical-stage biotech company specializing in protein degradation th...
Arvinas, a clinical-stage biotech company specializing in protein degradation therapies, announced management participation in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company will present preliminary clinical data from early monotherapy dose escalation cohorts of ARV-393 (Zaloblideg), a PROTAC BCL6 degrader, at the 2026 American Society of Hematology Annual Meeting, including safety, pharmacokinetics, and pharmacodynamics data.
The article highlights three blue-chip dividend stocks offering yields above 4%...
The article highlights three blue-chip dividend stocks offering yields above 4% with strong dividend coverage and growth potential: PepsiCo (54-year dividend growth streak, 4.2% yield), Pfizer (16-year consecutive raises, 5.8% yield), and AT&T (sustainable 47% payout ratio, trading at low valuation multiples). All three are positioned to maintain their dividends despite current headwinds.
Johnson & Johnson's oncology sales grew 16.8% to $22 billion in the first nine m...
Johnson & Johnson's oncology sales grew 16.8% to $22 billion in the first nine months of 2026, driven by blockbuster drug Darzalex and newer therapies like Carvykti and Tecvayli. The company aims to become the #1 oncology player by 2030 with over $50 billion in sales, supported by a robust pipeline and recent FDA approvals. However, J&J shares are trading at a premium valuation with declining earnings estimates, earning a Zacks Rank #4 (Sell) rating.
The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8%...
The Idiopathic Inflammatory Myositis (IIM) market is projected to grow at 16.8% CAGR through 2036, reaching significant expansion driven by rising disease awareness, improved diagnostics, and an expanding pipeline of targeted therapies. The market was valued at USD 714 million across the 7MM in 2025, with the US accounting for 55% of the market. Multiple pharmaceutical companies are advancing investigational treatments addressing unmet medical needs in dermatomyositis, polymyositis, and inclusion body myositis.
